Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20463440 | 0.88 | HTR2B (0.86) | HTR2B | |
| SCHEMBL2514536 | 0.85 | HTR2B (0.61) | HTR2BSMN1; SMN2 | |
| SCHEMBL742415 | 0.85 | HTR2B (0.61) | HTR2BSMN1; SMN2 | |
| SCHEMBL2520100 | 0.85 | HTR2B (0.61) | HTR2BSMN1; SMN2 | |
| SCHEMBL20456202 | 0.84 | HTR2B (0.72) | HTR2BSMN1; SMN2 | |
| SCHEMBL21393307 | 0.84 | HTR2B (0.63) | HTR2BSMN1; SMN2 | |
| SCHEMBL14413511 | 0.84 | SMN1; SMN2 (0.68) | HTR2BSMN1; SMN2 | |
| SCHEMBL1299048 | 0.84 | HTR2B (1.00) | HTR2B | |
| SCHEMBL19924942 | 0.83 | POLB (0.64) | HTR2BSMN1; SMN2 | |
| SCHEMBL2307512 | 0.82 | GRIN2B (0.72) | HTR2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018144900-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2007117778-A9 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS INC (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1986747-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | Kalypsys, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | NOS2, NOS1, NQO2 | HTR2B 3435/4885SMN1; SMN2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.